vTv Therapeutics Past Earnings Performance
Past criteria checks 0/6
vTv Therapeuticshan disminuido a un ritmo medio anual de -10.9%, mientras que en la industria Biotechs los ingresos han sido de growing a 17.4% anuales. Los ingresos han sido declining a una tasa media anual de 33.3%.
Key information
-11.6%
Earnings growth rate
27.1%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -37.8% |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?
May 11vTv Therapeutics GAAP EPS of -$0.04
Aug 16vTv stock soars 18% on $10M equity investment by CinRx Pharma
Jul 25We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully
Aug 17The Director of vTv Therapeutics Inc. (NASDAQ:VTVT), Richard Nelson, Just Bought A Few More Shares
Mar 03vTv Therapeutics inks licensing deal for HPP971, shares up 11%
Dec 15MacAndrews & Forbes buys 625K shares of vTv Therapeutics
Dec 11vTv Therapeutics raises $47M via stock purchase agreement
Nov 24Revenue & Expenses BreakdownBeta
How vTv Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -20 | 12 | 0 |
30 Sep 23 | 0 | -22 | 12 | 0 |
30 Jun 23 | 0 | -19 | 12 | 0 |
31 Mar 23 | 0 | -17 | 10 | 0 |
31 Dec 22 | 2 | -19 | 12 | 0 |
30 Sep 22 | 2 | -21 | 15 | 0 |
30 Jun 22 | 5 | -18 | 14 | 0 |
31 Mar 22 | 5 | -16 | 15 | 0 |
31 Dec 21 | 4 | -13 | 11 | 0 |
30 Sep 21 | 10 | -5 | 9 | 0 |
30 Jun 21 | 7 | -5 | 8 | 0 |
31 Mar 21 | 7 | -8 | 7 | 0 |
31 Dec 20 | 6 | -8 | 7 | 0 |
30 Sep 20 | 0 | -15 | 7 | 0 |
30 Jun 20 | 0 | -17 | 8 | 0 |
31 Mar 20 | 2 | -17 | 9 | 0 |
31 Dec 19 | 3 | -18 | 9 | 0 |
30 Sep 19 | 7 | -15 | 9 | 0 |
30 Jun 19 | 11 | -11 | 9 | 0 |
31 Mar 19 | 11 | -12 | 9 | 0 |
31 Dec 18 | 12 | -9 | 9 | 0 |
30 Sep 18 | 8 | -11 | 10 | 0 |
30 Jun 18 | 5 | -14 | 10 | 0 |
31 Mar 18 | 2 | -15 | 11 | 0 |
31 Dec 17 | 0 | -16 | 11 | 0 |
30 Sep 17 | 0 | -16 | 11 | 0 |
30 Jun 17 | 0 | -16 | 10 | 0 |
31 Mar 17 | 0 | -17 | 10 | 0 |
31 Dec 16 | 1 | -16 | 10 | 0 |
30 Sep 16 | 1 | -15 | 10 | 0 |
30 Jun 16 | 1 | -16 | 10 | 0 |
31 Mar 16 | 1 | -22 | 10 | 0 |
31 Dec 15 | 1 | -27 | 9 | 0 |
30 Sep 15 | 1 | -32 | 9 | 0 |
30 Jun 15 | 1 | -34 | 8 | 0 |
31 Mar 15 | 2 | -31 | 9 | 0 |
31 Dec 14 | 2 | -36 | 12 | 0 |
31 Dec 13 | 1 | -48 | 8 | 0 |
Ingresos de calidad: VTVT actualmente no es rentable.
Margen de beneficios creciente: VTVT actualmente no es rentable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Tendencia de beneficios: VTVT no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 10.9% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de VTVT en el último año con su media de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: VTVT no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Biotechs (-42.7%).
Return on Equity
Alto ROE: VTVTEl pasivo de la empresa supera su activo, por lo que es difícil calcular su Rentabilidad de los fondos propios.